| Year |
Citation |
Score |
| 2011 |
Yamamoto M, Ikezu T. CCR2 chemokine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-7. DOI: 10.1016/B978-008055232-3.60187-4 |
0.484 |
|
| 2011 |
Yamamoto M, Ikezu T. CCR1 chemokine receptor Xpharm: the Comprehensive Pharmacology Reference. 1-10. DOI: 10.1016/B978-008055232-3.60185-0 |
0.489 |
|
| 2009 |
Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, β-amyloidosis, and Learning Impairment of APP/PS1 Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 803-809. PMID 28189021 DOI: 10.1038/mt.2009.44 |
0.779 |
|
| 2009 |
Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. Plos One. 4: e6197. PMID 19593388 DOI: 10.1371/Journal.Pone.0006197 |
0.807 |
|
| 2009 |
Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 803-9. PMID 19277012 DOI: 10.1038/Mt.2009.44 |
0.8 |
|
| 2008 |
Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. Journal of Immunology (Baltimore, Md. : 1950). 181: 3877-86. PMID 18768842 DOI: 10.4049/Jimmunol.181.6.3877 |
0.794 |
|
| 2008 |
Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL, Kaibuchi K, Persidsky Y, Ikezu T. Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. The American Journal of Pathology. 172: 521-33. PMID 18187566 DOI: 10.2353/Ajpath.2008.070076 |
0.694 |
|
| 2008 |
Ikezu T, Kiyota T, Yamamoto M, Xu J, Jacobsen MT, Okuyama S. O1-04-08: Therapeutic application of anti-inflammatory cytokines an Abeta-induced cognitive dysfunction Alzheimer's & Dementia. 4: T116-T117. DOI: 10.1016/J.Jalz.2008.05.245 |
0.681 |
|
| 2007 |
Yamamoto M, Kiyota T, Walsh SM, Ikezu T. Kinetic analysis of aggregated amyloid-beta peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 2: 213-21. PMID 18040846 DOI: 10.1007/S11481-006-9049-8 |
0.803 |
|
| 2007 |
Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. The American Journal of Pathology. 170: 680-92. PMID 17255335 DOI: 10.2353/Ajpath.2007.060378 |
0.739 |
|
| 2005 |
Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, Ikezu T. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. The American Journal of Pathology. 166: 1475-85. PMID 15855647 DOI: 10.1016/S0002-9440(10)62364-4 |
0.803 |
|
| Show low-probability matches. |